Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: June 24, 2024
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 66,000 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on May 6, 2024, which is part of a broader DKK 20 billion programme authorized for a 12-month period beginning February 6, 2024.
Key Financial Metrics
This filing focuses on capital allocation activities rather than operational financial performance. Key metrics provided include:
- Repurchase Programme Cap: DKK 20 billion (12-month period starting Feb 6, 2024).
- Specific Tranche Cap: DKK 2.2 billion (May 7, 2024 to August 5, 2024).
- Total Repurchased (since Feb 6, 2024): 9,884,290 B shares.
- Total Value Repurchased (since Feb 6, 2024): DKK 8,610,201,494.
- Average Purchase Price (since Feb 6, 2024): DKK 871.10 per B share.
- Treasury Shares Held: 11,249,854 B shares (0.3% of share capital).
- Outstanding Shares: 4,465,000,000 (including treasury shares).
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes vs. Prior Period
The filing details transactions executed between June 17, 2024, and June 21, 2024, under the specific tranche initiated on May 6, 2024:
- Shares Purchased (June 17-21): 180,995 B shares.
- Value Purchased (June 17-21): Approximately DKK 178.15 million.
- Average Price Range: DKK 979.90 to DKK 986.99 per share during this specific week.
- Accumulated under May 6 Programme: 1,150,040 shares valued at DKK 1,082,466,722 as of June 21, 2024.
Guidance, Outlook, and Management Commentary
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 20 billion during the 12-month period beginning February 6, 2024.
Management Commentary: The company reaffirms its purpose to drive change to defeat serious chronic diseases, built upon its heritage in diabetes. The share repurchase is executed in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond standard regulatory compliance for share buybacks.
Important Facts for Investor Verification
- Verify the remaining capacity of the DKK 20 billion share repurchase programme (approx. DKK 11.39 billion remaining as of June 21, 2024).
- Confirm the impact of treasury shares (0.3% of capital) on earnings per share calculations in upcoming earnings reports.
- Monitor the average purchase price trend, which has risen from DKK 871.10 (programme average) to nearly DKK 987 in late June 2024.
- Check the company website (novonordisk.com) for daily transaction details as required by the filing.